PYC is in the business of drug discovery and development. It...

PYC is in the business of drug discovery and development. It aims to pair precise and powerful RNA therapeutics, which target the root cause of a disease, with its proprietary delivery system based on its extensive library of cell penetrating peptides.

To compete in the game of drug discovery, to succeed and grow, drug developers need a cutting edge, powerful drug discovery engine which is capable of rapidly screening, identifying and derisking novel drug candidates. AI  is being rapidly adopted by pharma to turbo-charge drug discovery and development.

https://blog.petrieflom.law.harvard...telligence-is-revolutionizing-drug-discovery/

https://www.nature.com/articles/d41586-023-03172-6


https://www.frontiersin.org/articles/10.3389/fgene.2022.870795/full

There has been an astonishing number of AI- related pharma deals in recent months:

Eli Lilly, Novo Nordisk, Merck
https://www.globalxetfs.com.au/the-next-big-theme-october-2023/

Alexion
https://www.pharmaceutical-technology.com/news/alexion-verge-drug-deal/?cf-view

Genentech
https://www.biopharmadive.com/news/genentech-nvidia-biotech-ai-drug-research/700221/

Sanofi
https://www.fiercebiotech.com/biote...ply-aqemias-physics-algorithms-drug-discovery

As a drug discoverer and developer with the ambition of moving forward at least one new drug candidate each year, PYC needs to keep up with the game.

For the value that could be potentially derived from this collaboration, I think that A$5.5m is an absolute bargain.